An observational study in Multiple Sclerosis, Depression and Anxiety, sponsored by King's College London. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-01-24.
Sponsored by King's College London · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The aim of this pre-post observational study is to explore if it is feasible to implement 1) routine mental health screening and b) an online Cognitive Behavioural Therapy (CBT) treatment for anxiety and/or depression (named COMPASS-MS) for people living with Multiple Sclerosis (MS) (PwMS) and co-morbid psychological distress in routine care.
The aim of the project is to conduct a feasibility study regarding the implementation of a) routine mental health screening and b) the COMPASS-MS programme as a low-intensity online CBT treatment for anxiety and/or depression in a large English National Health Service (NHS) secondary care MS Clinic.
The intervention will be supported by COMPASS-trained therapists, who will receive supervision from a Clinical Health Psychologist and the Multi-Disciplinary Team (Quantitative Study A). We will also conduct two nested qualitative studies to explore the barriers and facilitators of implementing the COMPASS-MS care pathway locally at King's Hospital (KCH) (Qualitative Study A) and scaling it across Neurology Services outside KCH (Qualitative Study B).
3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.
This study's planned enrollment of 102 is close to the median of 100 across 972 observational studies indexed under Multiple Sclerosis.
Browse Multiple Sclerosis studies →King's College London is the lead sponsor of 524 studies on the registry; 130 are open to participants now.
Counted across the registry records on this site, refreshed daily.
People living with Multiple Sclerosis (MS) and co-morbid psychological distress Healthcare professionals and Key stakeholders of people living with MS and co-morbid psychological distress
Patients will be eligible for inclusion for the COMPASS-MS intervention if they are:
i. A score of ≥ 5 on the nine item self-report measure of depression: PHQ-9 (Kroenke et al., 2001) AND/OR ii. A score of ≥ 5 on the seven item self-report measure of anxiety: GAD-7 (Spitzer et al., 2006).
OR iii. A score of ≥ 10 on the composite measure of depression and anxiety PHQ-ADS (Kroenke et al., 2016).
AND iv. Distress is related to their MS (i.e. answer "yes" or "sometimes" to "Is your distress linked to your MS?"
The below eligibility criteria apply to HCPs who have experience in engaging with COMPASS-MS care pathways at King's College Hospital (KCH).
Healthcare providers (HCPs) will be eligible for inclusion if they meet all or any of the below criteria:
Key Stakeholder Inclusion Criteria
Key Stakeholders from Neurology services external to KCH will be invited to take part in an interview if they meet all or any of the below criteria:
Digital CBT to treat psychological distress in Multiple Sclerosis (MS)
Psychological Distress (primary outcome for a future full scale trial).
The investigators will measure general psychological distress using the Patient Health Questionnaire Anxiety and Depression Scale (PHQ-ADS). This includes 9 items from the Patient Health Questionnaire and 7 items from the Generalised Anxiety Disorder Scale. Each item is responded to on a 4-point Likert Scale (0-3) (minimum score: 0, maximum score: 48). Higher scores indicate higher levels of depression and anxiety.
Time frame: baseline and 12 week follow up
Reach of screening and COMPASS MS intervention
- The clinical team will collect data on the route of referral to mental health team (completed routine screening, was referred/self-referred).
Time frame: Baseline only
Reach of screening and COMPASS MS intervention
- If referred, the clinical team will collect data on the who the referring clinician is and their professional background.
Time frame: Baseline only
Reach of screening and COMPASS MS intervention
- The clinical team will collect data on patient attendance at triage appointment and care pathway recommended (including referral to COMPASS-MS)
Time frame: Baseline only
Reach of screening and COMPASS MS intervention
- the clinical team will collect data on the outcome of screening (e.g eligible for COMPASS-MS intervention or not)
Time frame: Baseline only
Efficacy: psychological outcomes
- The investigators will measure Intolerance of Uncertainty using the Intolerance of Uncertainty Scale-12 item. Items are rated on a 5-point Likert scale (minimum score: 12, maximum score: 60). Higher scores indicate a greater intolerance of uncertainty.
Time frame: baseline and 12 week follow up
Efficacy: psychological outcomes
- The investigators will measure Expression of emotion will be measured using the Beliefs about Emotions Scale.
Time frame: baseline and 12 week follow up
Efficacy: Psycho-social outcomes
- The investigators will measure Healthcare usage using the 4 service use items from the Client Service Receipt Inventory (CSRI).
Time frame: baseline and 12 week follow up
Implementation of COMPASS
The investigators will investigate the implementation of COMPASS by collecting descriptive data on the number of patients who require digital support to use COMPASS-MS
Time frame: post treatment (12 week follow up)
Implementation of COMPASS
The investigators will investigate the implementation of COMPASS by collecting descriptive data on patient adherence to COMPASS online sessions.
Time frame: post treatment (12 week follow up)
Implementation of COMPASS
The investigators will investigate the implementation of COMPASS by collecting descriptive data on the number and duration of therapist calls attended.
Time frame: post treatment (12 week follow up)
Implementation of COMPASS
The investigators will investigate the implementation of COMPASS by collecting descriptive data on the dropout rate of COMPASS.
Time frame: post treatment (12 week follow up)
Adoption
We will qualitatively explore the Adoption of COMPASS. We will conduct two nested qualitative studies. 1) we will interview patients and healthcare professionals at Kings College Hospital to explore the barriers and facilitators of implementing the COMPASS-MS care pathway locally at King's Hospital (KCH) (Qualitative Study A) 2 ) we will interview key stakeholders outside of KCH to explore the barriers and facilitators of scaling it across Neurology Services outside KCH (Qualitative Study B).
Time frame: 12 weeks follow up (post treatment)
No study locations are listed for this record.
Start is estimated for Feb 2024; primary completion for Feb 2025, 12 months later.
Of 336 non-industry observational studies under Multiple Sclerosis, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 81. This study's planned 12 months is below that.
Counting every sponsor, half of 427 studies reached it within 41 months; a quarter within 15 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.